BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27044584)

  • 1. Adherence to evidence-based drug therapies after myocardial infarction: is geographic variation related to hospital of discharge or primary care providers? A cross-classified multilevel design.
    Di Martino M; Alagna M; Cappai G; Mataloni F; Lallo A; Perucci CA; Davoli M; Fusco D
    BMJ Open; 2016 Apr; 6(4):e010926. PubMed ID: 27044584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
    Di Martino M; Alagna M; Lallo A; Gilmore KJ; Francesconi P; Profili F; Scondotto S; Fantaci G; Trifirò G; Isgrò V; Davoli M; Fusco D
    BMC Cardiovasc Disord; 2021 Apr; 21(1):180. PubMed ID: 33853534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to Long-Acting Bronchodilators After Discharge for COPD: How Much of the Geographic Variation is Attributable to the Hospital of Discharge and How Much to the Primary Care Providers?
    Di Martino M; Ventura M; Cappai G; Lallo A; Davoli M; Agabiti N; Fusco D
    COPD; 2017 Feb; 14(1):86-94. PubMed ID: 27419396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Organisational determinants of adherence to secondary prevention medications after acute myocardial infarction].
    Perrone E; Lenzi J; Avaldi VM; Castaldini I; Protonotari A; Rucci P; Piccinni C; Morini M; Fantini MP
    Epidemiol Prev; 2015; 39(2):106-14. PubMed ID: 26036739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarction.
    Di Martino M; Kirchmayer U; Agabiti N; Bauleo L; Fusco D; Perucci CA; Davoli M
    BMJ Open; 2015 Jun; 5(6):e007866. PubMed ID: 26063569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
    Soldati S; Di Martino M; Rosa AC; Fusco D; Davoli M; Mureddu GF
    BMC Cardiovasc Disord; 2021 Sep; 21(1):466. PubMed ID: 34565326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the role of hospitals and office-based physicians in timely provision of statins following acute myocardial infarction: a secondary analysis of a nationwide cohort using cross-classified multilevel models.
    Schang L; Koller D; Franke S; Sundmacher L
    BMJ Open; 2019 Oct; 9(10):e030272. PubMed ID: 31619423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-hospital myocardial infarction and adherence to evidence-based drug therapies: a real-world evaluation.
    Soldati S; Di Martino M; Castagno D; Davoli M; Fusco D
    BMJ Open; 2021 Feb; 11(2):e042878. PubMed ID: 33550255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy.
    Kirchmayer U; Agabiti N; Belleudi V; Davoli M; Fusco D; Stafoggia M; Arcà M; Barone AP; Perucci CA
    J Clin Pharm Ther; 2012 Feb; 37(1):37-44. PubMed ID: 21294760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adherence to chronic polytherapy in secondary prevention of myocardial infarction: limits and perspectives.].
    Di Martino M; Lallo A; Davoli M; Fusco D
    Recenti Prog Med; 2019 Jan; 110(1):7-9. PubMed ID: 30720011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality.
    Mathews R; Wang W; Kaltenbach LA; Thomas L; Shah RU; Ali M; Peterson ED; Wang TY
    Circulation; 2018 May; 137(20):2128-2138. PubMed ID: 29386204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methodology and rules for measuring adherence: beyond the doctor-patient combination.].
    Alagna M; Di Martino M
    Recenti Prog Med; 2021 Sep; 112(9):557-560. PubMed ID: 34392318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population.
    Huber CA; Meyer MR; Steffel J; Blozik E; Reich O; Rosemann T
    Clin Ther; 2019 Jan; 41(1):107-117. PubMed ID: 30591287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of adherence to evidence-based therapy after acute myocardial infarction.
    Hamood H; Hamood R; Green MS; Almog R
    Eur J Prev Cardiol; 2016 Jun; 23(9):975-85. PubMed ID: 26198723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of antibiotic prescription in pediatric outpatients in Italy: the role of local health districts and primary care physicians in determining variation. A multilevel design for healthcare decision support.
    Di Martino M; Lallo A; Kirchmayer U; Davoli M; Fusco D
    BMC Public Health; 2017 Nov; 17(1):886. PubMed ID: 29149875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction.
    Faridi KF; Peterson ED; McCoy LA; Thomas L; Enriquez J; Wang TY
    JAMA Cardiol; 2016 May; 1(2):147-55. PubMed ID: 27437885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.
    Margulis AV; Choudhry NK; Dormuth CR; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1088-97. PubMed ID: 21538672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry.
    Urbinati S; Olivari Z; Gonzini L; Savonitto S; Farina R; Del Pinto M; Valbusa A; Fantini G; Mazzoni A; Maggioni AP;
    Eur J Prev Cardiol; 2015 Dec; 22(12):1548-56. PubMed ID: 25452625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.